Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24723670 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24723975 | 0.82 | CHRM2 (0.39) | CHRM2CHRM1CHRM3PREPABCB1 | |
| SCHEMBL19386737 | 0.78 | CHRM2 (0.43) | CHRM2CHRM1CHRM3PREPKDM4E | |
| SCHEMBL5149749 | 0.78 | CHRM2 (0.52) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2915087 | 0.77 | CHRM2 (0.45) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL12333780 | 0.77 | CHRM2 (0.56) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL26805930 | 0.77 | CHRM2 (0.56) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL880528 | 0.77 | CHRM2 (0.56) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL21441814 | 0.77 | CHRM2 (0.56) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL28713687 | 0.76 | CHRM2 (0.51) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | CHRM2 2273/4885CHRM1 2962/4885CHRM3 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.